Highlight Day 2-Central Nervous System Tumors

Highlights of the Day:Central Nervous System Tumors

Presented By Michael Prados at 2014 ASCO Annual Meeting

Slide 2

Presented By Michael Prados at 2014 ASCO Annual Meeting

R9802 SCHEMA

Presented By Michael Prados at 2014 ASCO Annual Meeting

Data Maturity

Presented By Michael Prados at 2014 ASCO Annual Meeting

Progression-Free SurvivalASCO 2014

Presented By Michael Prados at 2014 ASCO Annual Meeting

Overall SurvivalASCO 2014

Presented By Michael Prados at 2014 ASCO Annual Meeting

ASCO 2014: Overall Survival

Presented By Michael Prados at 2014 ASCO Annual Meeting

Cox Proportional Hazards Model for Overall Survival (n=251)

Presented By Michael Prados at 2014 ASCO Annual Meeting

Conclusions (Prognostic Variables)

Presented By Michael Prados at 2014 ASCO Annual Meeting

Conclusions (Survival)

Presented By Michael Prados at 2014 ASCO Annual Meeting

Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779)/RT followed by CCI-779 versus chemo-irradiation with temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II study.

Presented By Michael Prados at 2014 ASCO Annual Meeting

EORTC 26082/22081: Study Design

Presented By Michael Prados at 2014 ASCO Annual Meeting

EORTC 26082/22081: Overall survival

Presented By Michael Prados at 2014 ASCO Annual Meeting

Conclusions

Presented By Michael Prados at 2014 ASCO Annual Meeting

Correlation of Molecular Subtypes with Survival in AVAglio

Presented By Michael Prados at 2014 ASCO Annual Meeting

Introduction

Presented By Michael Prados at 2014 ASCO Annual Meeting

AVAglio Trial Design and Primary Endpoints

Presented By Michael Prados at 2014 ASCO Annual Meeting

ITT and Biomarker-Evaluable Populations

Presented By Michael Prados at 2014 ASCO Annual Meeting

Background: Glioblastoma Gene Expression Subtypes

Presented By Michael Prados at 2014 ASCO Annual Meeting

Results: BEV Treatment Impacted PFS in Proneural and Mesenchymal Subtypes

Presented By Michael Prados at 2014 ASCO Annual Meeting

Results: BEV Effect on OS was Evident Only in the Proneural Subtype

Presented By Michael Prados at 2014 ASCO Annual Meeting

Results: Effect of BEV on OS was Significant in Univariate and Multivariate Analyses

Presented By Michael Prados at 2014 ASCO Annual Meeting

Conclusions

Presented By Michael Prados at 2014 ASCO Annual Meeting